Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma - PubMed (original) (raw)
Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma
C D Morris et al. Clin Orthop Relat Res. 2001 Jan.
Abstract
Prognostic biologic factors that can be assessed at the time of diagnosis for patients with osteogenic sarcoma have not been identified. The current study was designed to evaluate the prognostic significance of the human epidermal growth factor receptor 2 as it relates to histologic response to preoperative chemotherapy and event-free survival. A retrospective immunohistochemical study was performed on material from patients who were newly diagnosed with osteogenic sarcoma who were treated according to the T12 protocol from the authors' institution between 1986 to 1993. Staining for HER2/erbB-2 was accomplished using standard monoclonal antibodies and methods. At the time of initial biopsy, 42.6% of the samples showed HER2/erbB-2 overexpression. Higher levels of expression were observed in samples from patients with clinically detectable metastases at initial presentation and at relapse. Expression of HER2/erbB-2 correlated with inferior event-free survival in patients with nonmetastatic disease (47% versus 79% at 5 years). In addition, HER2/erbB-2 expression was associated with significantly less tumor necrosis after preoperative chemotherapy as determined by the Huvos grading system. These data suggest that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator and clinical trials using antibodies that target this receptor should be considered for the treatment of patients with osteogenic sarcoma.
Similar articles
- Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA. Gorlick R, et al. J Clin Oncol. 1999 Sep;17(9):2781-8. doi: 10.1200/JCO.1999.17.9.2781. J Clin Oncol. 1999. PMID: 10561353 - Excision of pulmonary metastases of osteogenic sarcoma of the limbs.
Antunes M, Bernardo J, Salete M, Prieto D, Eugénio L, Tavares P. Antunes M, et al. Eur J Cardiothorac Surg. 1999 May;15(5):592-6. doi: 10.1016/s1010-7940(99)00098-6. Eur J Cardiothorac Surg. 1999. PMID: 10386402 Clinical Trial. - Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H. Kurebayashi J, et al. Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8. Breast Cancer. 2015. PMID: 23749689 - Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L. Siena S, et al. Ann Oncol. 2018 May 1;29(5):1108-1119. doi: 10.1093/annonc/mdy100. Ann Oncol. 2018. PMID: 29659677 Free PMC article. Review. - The predictive value of HER2 in breast cancer.
Piccart M, Lohrisch C, Di Leo A, Larsimont D. Piccart M, et al. Oncology. 2001;61 Suppl 2:73-82. doi: 10.1159/000055405. Oncology. 2001. PMID: 11694791 Review.
Cited by
- Expression of HER-2 in surgical specimen and biopsy as a biomarker of metastasis in patients with osteosarcoma: a meta-analysis.
Zhou J, Wang W, Yan Q, Luo Y. Zhou J, et al. Transl Cancer Res. 2019 Aug;8(4):1129-1136. doi: 10.21037/tcr.2019.06.26. Transl Cancer Res. 2019. PMID: 35116855 Free PMC article. - Coexistence of HER2, Ki67, and p53 in Osteosarcoma: A Strong Prognostic Factor.
Mardanpour K, Rahbar M, Mardanpour S. Mardanpour K, et al. N Am J Med Sci. 2016 May;8(5):210-4. doi: 10.4103/1947-2714.183013. N Am J Med Sci. 2016. PMID: 27298815 Free PMC article. - Strategies and developments of immunotherapies in osteosarcoma.
Wan J, Zhang X, Liu T, Zhang X. Wan J, et al. Oncol Lett. 2016 Jan;11(1):511-520. doi: 10.3892/ol.2015.3962. Epub 2015 Nov 24. Oncol Lett. 2016. PMID: 26834853 Free PMC article. - Interaction between fatty acid synthase and human epidermal growth receptor 2 (HER2) in osteosarcoma cells.
Long XH, Zhao K, Zhang GM, Zhou Y, Zhou RP, Liu ZL, Zhang ZH. Long XH, et al. Int J Clin Exp Pathol. 2014 Dec 1;7(12):8777-83. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25674245 Free PMC article. - Genetically modified T-cell therapy for osteosarcoma.
DeRenzo C, Gottschalk S. DeRenzo C, et al. Adv Exp Med Biol. 2014;804:323-40. doi: 10.1007/978-3-319-04843-7_18. Adv Exp Med Biol. 2014. PMID: 24924183 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous